Blog
RSS FeedPosted by Michael Wonder on 10 Oct 2020
Health Canada approves Inqovi (decitabine and cedazuridine) oral therapy for two types of blood cancers, MDS and CMML
8 October 2020 - Oral drug can be taken at home, which may enable some patients to avoid some hospital visits. ...
Posted by Michael Wonder on 22 Sep 2020
Health Canada approves Inrebic (fedratinib), first new treatment in nearly a decade for patients living with myelofibrosis
21 September 2020 - Inrebic provides new, once-daily oral option for patients affected by rare bone marrow cancer. ...
Posted by Michael Wonder on 11 Sep 2020
Medexus reports Health Canada approval of Gleolan for use in guided surgical resection of high grade gliomas
10 September 2020 - Medexus Pharmaceuticals today announces that on 9 September 2020, it received a Notice of Compliance from ...
Posted by Michael Wonder on 10 Sep 2020
BeiGene announces acceptance and priority review by Health Canada of new drug submission for Brukinsa (zanubrutinib) in Waldenström’s macroglobulinaemia
9 September 2020 - BeiGene today announced that its new drug submission for Brukinsa (zanubrutinib) for the treatment of patients with ...
Posted by Michael Wonder on 20 Aug 2020
Health Canada grants market authorization for Tecentriq in combination with bevacizumab, the first immunotherapy combination treatment, for the most common form of liver cancer
19 August 2020 - Tecentriq in combination with bevacizumab improved overall survival and progression-free survival compared to the previous standard of ...
Posted by Michael Wonder on 16 Aug 2020
Piqray is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR positive, HER2 negative advanced breast cancer
13 August 2020 - Approval is based on results from SOLAR-1, where Piqray in combination with fulvestrant nearly doubled median progression-free ...
Posted by Michael Wonder on 12 Aug 2020
Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) combined with limited chemotherapy for the treatment of metastatic non-small cell lung cancer
11 August 2020 - CheckMate-9LA trial results demonstrated superior overall survival versus chemotherapy, regardless of PD-L1 expression or tumour histology. ...
Posted by Michael Wonder on 04 Aug 2020
Janssen announces Health Canada approval of Darzalex SC, a new subcutaneous formulation for the treatment of patients with multiple myeloma
4 August 2020 - Darzalex SC reduces administration time from hours to minutes and demonstrates consistent efficacy with a reduction in ...
Posted by Michael Wonder on 09 Jul 2020
Sarclisa (isatuximab for injection) now available in Canada for patients with relapsed and refractory multiple myeloma
8 July 2020 - First and only anti-CD38 antibody in combination with pomalidomide and dexamethasone to be approved in Canada. ...
Posted by Michael Wonder on 09 Jul 2020
Astex Pharmaceuticals, Taiho Oncology and Otsuka Pharmaceutical announce Health Canada approval of Inqovi (decitabine and cedazuridine) tablets, oral hypomethylating agent therapy for intermediate and high-risk MDS and C
7 July 2020 - Inqovi is the first orally administered hypomethylating agent approved by the FDA and Health Canada. ...
Posted by Michael Wonder on 23 Jun 2020
Deciphera announces Health Canada’s authorisation of Qinlock (ripretinib) for the treatment of fourth-line gastro-intestinal stromal tumour
22 June 2020 - Qinlock significantly improved progression-free survival and showed clinically meaningful overall survival in global INVICTUS Phase 3 study. ...
Posted by Michael Wonder on 17 Jun 2020
Health Canada Approves Xtandi (enzalutamide) for the treatment of metastatic castration-sensitive prostate cancer
16 June 2020 - Xtandi is the first and only androgen receptor-axis-targeted therapy approved by Health Canada in three clinical ...
Posted by Michael Wonder on 21 May 2020
Health Canada grants market authorisation to Rozlytrek (entrectinib) for ROS1-positive, locally advanced or metastatic non-small cell lung cancer patients, not previously treated with crizotinib
20 May 2020 - Data show responses in 73% of patients who were treated with Rozlytrek. ...
Posted by Michael Wonder on 06 May 2020
AbbVie receives Health Canada approval for the combination of Venclexta (venetoclax) with obinutuzumab for patients with previously untreated chronic lymphocytic leukaemia
5 May 2020 - Venclexta (venetoclax) plus obinutuzumab is the first chemotherapy-free, fixed-duration combination regimen approved by Health Canada for patients ...
Posted by Michael Wonder on 29 Apr 2020
Health Canada approves Rozlytrek (entrectinib) for NTRK gene fusion-positive solid tumours in locally advanced or metastatic patients
28 April 2020 - Data show more than half of trial patients across all 10 tumour types studied had responses to ...